Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $119.93 USD
Change Today +6.08 / 5.34%
Volume 1.8M
INCY On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

incyte corp (INCY) Key Developments

Incyte Corporation Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for Fiscal 2015

Incyte Corporation reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. For the quarter, total revenues were $162,984,000 against $99,582,000 for the same period of last year. Loss from operations was $7,394,000 against $26,187,000 for the same period of last year. Profit before provision for income taxes was $9,430,000 against loss before provision for income taxes of $36,803,000 for the same period of last year. Net income was $9,294,000 against net loss of $36,873,000 for the same period of last year. Net income per basic and diluted share was $0.05 against net loss per share of $0.22 for the same period of last year. For the six months, total revenues were $322,260,000 against $189,374,000 for the same period of last year. Loss from operations was $14,326,000 against loss of $49,123,000 for the same period of last year. Loss before provision for income taxes was $8,560,000 against $70,711,000 for the same period of last year. Net loss was $9,063,000 against $70,830,000 for the same period of last year. Net loss per basic and diluted share was $0.05 against $0.43 for the same period of last year. The company now expects that 2015 net product revenues from Jakafi will be in the range of $560 million to $575 million, an increase from the previous range of $525 million to $565 million, driven by strong underlying demand.

Incyte Corporation to Report Q2, 2015 Results on Aug 04, 2015

Incyte Corporation announced that they will report Q2, 2015 results at 10:00 AM, US Eastern Standard Time on Aug 04, 2015

Incyte Corporation, Q2 2015 Earnings Call, Aug 04, 2015

Incyte Corporation, Q2 2015 Earnings Call, Aug 04, 2015

Incyte Corporation and Vanderbilt-Ingram Cancer Center Establish Multi-Year Oncology Research Alliance

Incyte Corporation announced that it has entered into a multi-year research support and collaboration agreement with Vanderbilt-Ingram Cancer Center (VICC) at Vanderbilt University Medical Center (VUMC), whereby Incyte will provide funding for certain aspects of Vanderbilt’s cancer research activities. This alliance is designed to develop an improved understanding of basic cancer biology and the mechanisms of action of certain Incyte-proprietary compounds, as well as identify and develop novel approaches to patient selection which may enable new therapeutic opportunities in oncology.

ImmunoVaccine Inc. Collaborates with Incyte Corporation to Evaluate Novel Immunotherapy Combination for Patients with Platinum sensitive Ovarian Cancer

Immunovaccine Inc. announced that it has entered into a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the combination of Immunovaccine's novel T cell activating immunotherapy, DPX-Survivac, with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). Immunovaccine and Incyte will co-fund and conduct a multicenter, open-label Phase 1B study to evaluate the safety, tolerability and efficacy of the novel combination in platinum-sensitive ovarian cancer patients who are at high risk of recurrence. The investigational new drug (IND) application for the study, which will test the triple combination of DPX-Survivac, epacadostat and low dose oral cyclophosphamide, is expected to be filed in 2015 in the U.S. and Canada and the study is expected to enroll approximately 20 patients. Results from this study may lead to an expansion of the clinical collaboration to investigate other cancers. DPX-Survivac and epacadostat both target pathways that have been linked to cancer progression, namely survivin and IDO1. High levels of survivin and IDO1 are found in a broad range of cancers, including ovarian cancer, and individually have been shown to correlate with poor patient outcomes. DPX-Survivac is designed to activate T cells of the immune system to recognize survivin-expressing cancer cells. Epacadostat, on the other hand, is designed to inhibit IDO1-mediated immune suppression in the tumor microenvironment. It is therefore hypothesized that co-administration of these immunotherapies may lead to enhanced anti-tumor effects by both activating the immune system to recognize the cancer and simultaneously weakening its defenses.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INCY:US $119.93 USD +6.08

INCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $63.15 USD +1.98
ARIAD Pharmaceuticals Inc $9.89 USD +2.91
BioMarin Pharmaceutical Inc $133.18 USD +2.29
Jazz Pharmaceuticals PLC $172.82 USD +2.05
Vertex Pharmaceuticals Inc $134.05 USD +0.30
View Industry Companies
 

Industry Analysis

INCY

Industry Average

Valuation INCY Industry Range
Price/Earnings 100.0x
Price/Sales 33.3x
Price/Book 391.7x
Price/Cash Flow 1,629.2x
TEV/Sales 31.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.